Pazopanib is an approved treatment for renal cell carcinoma and a second-line treatment for nonadipocytic soft-tissue sarcoma. However, its clinical efficacy is limited by its cardiovascular side effects. Pazopanib and other vascular endothelial growth factor receptor tyrosine kinase inhibitors have been associated with the development of hypertension, QT interval prolongation, and other cardiovascular events; however, these mechanisms are largely unknown. Gaining a deeper understanding of these mechanisms is essential for the development of appropriate surveillance strategies and possible diagnostic biomarkers to allow us to monitor patients and modulate therapy prior to significant cardiac insult. This approach will be vital in keeping patients on these life-saving therapies and may be applicable to other tyrosine kinase inhibitors as well. In this review, we provide a comprehensive overview of the preclinical and clinical side effects of pazopanib with a focus on the mechanisms responsible for its toxicity to the cardiovascular system.
Introduction
Kidney cancer is the 16th most common cause of death worldwide. 1 Renal cell carcinoma (RCC) accounts for approximately 90% of all cases with kidney cancer with an estimated 337 800 diagnoses and 143 000 deaths per year worldwide. 1 The incidence and prevalence of RCC have been increasing over the last 50 years, and with the growth of the US elderly population, these numbers are only expected to continue to increase. Renal cell carcinoma is particularly morbid, and the overall 5-year survival rate of metastatic RCC is approximately 12%. 2 The incidence rate of RCC is highest among those >70 years of age, males, African Americans, and Hispanics. 2 Notably smoking is an independent risk factor for RCC development and individuals smoking >30 to 40 pack-years are 80% more likely to develop advanced RCC. 2 A 5-kg/m 2 increase in body mass index increases the risk of developing RCC by over 20%. 1 Of note, other risk factors for the development of RCC include hypertension (HTN), dialysis, and genetic disorders such as Von Hippel Lindau syndrome, hereditary papillary RCC, and Birt-Hogg-Dubé syndrome (characterized by multiple benign skin tumors, lung cysts, and a predisposition for kidney neoplasms). 2, 3 The vascular endothelial growth factor (VEGF) pathway plays an important role in tumor growth and angiogenesis. 4 Pazopanib, a VEGF inhibitor, is approved by the Food and Drug Administration (FDA) as a first-and second-line treatment for late stages of RCC and nonadipocytic soft-tissue sarcoma (STS), respectively. 5, 6 Pazopanib provides a higher quality of life and lower incidence of side effects compared to other VEGF inhibitors. 7 Despite its efficacy in RCC treatment, pazopanib can also cause a variety of adverse reactions including gastrointestinal upset, hypothyroidism, bone marrow toxicity, HTN, heart failure (HF), myocardial ischemia, and arterial thromboembolic events (Table 1) . 11 These side effects may be attributed to inhibition of intended kinases (on-target inhibition) or nonspecific inhibition of unintended kinases (off-target inhibition) 12 which is discussed later in this review. The cardiovascular side effects of pazopanib are especially concerning because cardiovascular comorbidities are common in patients with RCC (cancer and cardiovascular disease share many common risk factors). 13 Hence, the goal of this review is to gain a deeper understanding regarding the fundamental relationship between pazopanib and its cardiovascular side effects that may improve the treatment of RCC in the long term.
Pharmacology/Pharmacokinetics
Pazopanib is one of several tyrosine kinase inhibitors (TKIs) that have been FDA approved to treat metastatic RCC and advanced STS.
14 Small-molecule TKIs, including pazopanib, inhibit the activity of various receptor tyrosine kinases by competitively inhibiting Adenosine triphosphate (ATP) binding to the intracellular ATP-binding pocket. 14 Pazopanib contains an adenine-like ring that mimics the hydrogen bonding capability of ATP to several kinases and inhibits VEGF receptors, platelet-derived growth factor (PDGF) receptors, and stem cell factor receptors.
14 Pazopanib inhibition of VEGF signaling is primarily responsible for its antiangiogenic effects on tumor growth. Additionally, pazopanib inhibits other kinases such as fibroblast growth factor receptors 1 and 3, interleukin 2 receptor-inducible T-cell kinase, leukocyte-specific protein tyrosine kinase, and transmembrane glycoprotein receptor tyrosine kinase. 15 The ATP-binding pocket is highly conserved across the kinome, 16 allowing drugs such as pazopanib to serve as "multikinase" inhibitors. Notably multitargeting contributes to the efficacy of cancer treatments; however, this inherent lack of selectivity may underlie its cardiovascular toxicity.
Pazopanib is commercially available in 200 and 400 mg oral tablet forms.
14 The recommended dose is 800 mg taken once daily an hour before or 2 hours after food consumption.
14 Pazopanib takes 2 to 4 hours to reach peak absorption with a half-life of 30.9 hours, making daily dosing adequate for steady-state concentration.
14 The mean area under the concentration curve achieved at this dosage is 1037 hÁmg/mL with a C max of 58.1 mg/mL.
14 For patients with RCC, tumor shrinkage and progression-free survival are correlated with a sustained plasma concentration of at least 20.5 mg/mL over the course of treatment as assessed by C trough . Plasma concentration thresholds above this value do not provide an additional benefit and may increase toxicity. 17 It is advised that concurrent use of CYP3A4 inhibitors be avoided when on a pazopanib treatment regimen, as they may cause an increase in drug levels and lead to toxicity.
14 Dosage should be decreased to 400 mg daily if CYP3A4 inhibitors cannot be avoided.
14 Dosage may be decreased from 800 to 400 mg or 200 mg in patients who exhibit dose-limiting toxicity. 18 Therapeutic levels are achievable in these patients at lower dosages due to high interpatient variability regarding drug absorption and metabolism. Recent clinical trials are investigating pharmacokinetically guided dosing of pazopanib to account for this variability and optimize treatment. 19, 20 Specific Cardiovascular Adverse Effects Associated With Pazopanib
The cardiovascular toxic effects of targeted therapies represent a challenge in oncologic care that can drain patients emotionally and physically. Cardiovascular side effects lead to significant morbidity and mortality in patients with cancer and survivors. 21 Improving our fund of knowledge regarding cardiovascular side effects together with early intervention and surveillance will help contribute to improved clinical outcomes in both patients with cancer and survivors.
Hypertension
Hypertension is the most frequently observed cardiovascular adverse event in patients treated with anti-VEGF agents including pazopanib for metastatic RCC. 8, [22] [23] [24] Hypertension is associated with an increased risk of stroke, myocardial infarction (MI), and HF. 25 Wild-type mice that received 30 mg/kg of pazopanib twice daily developed a statistically significant increase in mean arterial pressure compared to control mice after 2 weeks of treatment. 26 In a randomized, double-blind, placebo-controlled phase 3 clinical trial in patients with advanced RCC, the incidence of HTN was nearly 40% in patients receiving pazopanib compared to only 10% in the placebo group. 8 Thirteen of 250 patients on pazopanib developed grade 3 adverse event HTN 8 which was defined according to the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 as a recurrent or persistent HTN (!24 hours) or a symptomatic increase by >20 mm Hg (diastolic) or to >150/100 if previously within normal, in addition to requiring >1 medication or more intensive treatment. 8 Additionally, a phase 3 randomized trial in patients with metastatic RCC that compared pazopanib and sunitinib (a similar TKI) as first-line therapies regarding efficacy and safety demonstrated that there were minimal between-group differences in HTN development. Approximately 257 of 554 and 223 of 548 patients developed HTN with pazopanib and sunitinib, respectively. Likewise, about 14% of patients in both the pazopanib and the sunitinib arms developed grade 3 adverse event HTN. 7 Notably, HTN also developed in approximately 37% of patients with recurrent glioblastoma in phase 2 trial of pazopanib (totaling 35 patients). Hypertension was manageable with antihypertensives and reversible with drug discontinuation. 27 Previous studies have suggested that HTN potentially serves as a predictive factor for better outcomes in patients receiving TKIs such as sunitinib [28] [29] [30] [31] ; however, this has yet to be proven for pazopanib. Data from a retrospective analysis based on European Organization for Research and Treatment of Cancer 62043 and 62072 trials in pazopanib-treated patients with advanced nonadipocytic STS has demonstrated that pazopanib-associated HTN had no correlation with progression-free survival and overall survival in these patients. 32 Further studies are required to properly delineate the viability of using HTN as a biomarker for pazopanib efficacy.
Blood pressure monitoring. The hypertensive response of pazopanib is rapid and its incidence is correlated with preexisting HTN. When administered at supratherapeutic concentrations (800 mg daily on an empty stomach for 7 days and 1600 mg with food for 1 day) in a double-blind, placebo-controlled, parallel-group study, pazopanib led to a clinically significant increase in blood pressure after only 8 days of treatment initiation. Blood pressure levels returned to near normal by 24 hours after the last treatment. 33 In clinical practice, pazopanibinduced HTN develops in the majority of patients within 4 weeks of starting pazopanib. 34 A recent retrospective analysis of 35 pazopanib-treated patients with advanced/metastatic RCC found that 57% of the patient cohort (20/35) developed any grade HTN and that more than half of these cases developed within 25 days of starting pazopanib. Preexisting HTN was a risk factor for pazopanib-induced HTN. 35 In order to mitigate insult to the cardiovascular system, blood pressure should be normalized according to the Eighth Joint National Committee (JNC-8) guidelines prior to starting pazopanib. We would recommend obtaining blood pressure measurements at baseline and after 1 week, 1 month, and 2 months after the initiation of pazopanib. Any increases in blood pressure should be treated according to current guidelines. Pazopanib-induced HTN is generally manageable with antihypertensives and reversible with discontinuation of therapy 15, 22, 35 ; however, a small percentage of patients will require a dose reduction. 22, 36 For these patients, it is recommended that the dosage of pazopanib be reduced incrementally to 400 mg daily and 200 mg daily followed by drug discontinuation in the case of severe HTN that is unresponsive to antihypertensive therapy. 14, 18 Due to high interpatient variability in drug absorption and metabolism, 22 ,37,38 a higher proportion of patients receiving the minimal available dose of pazopanib (200 mg) may fail to reach optimal therapeutic plasma levels (>20.5 mg/mL) 17 ; however, we believe that dose reduction is the best course of action in cases of unmanageable HTN.
The optimal choice of antihypertensive medication for these patients remains a subject of ongoing investigation. There are no specific guidelines for the management of HTN induced by anti-VEGF therapy. Hypertension should be managed according to each patient's comorbidities and JNC-8 guidelines with the goal of mitigating cardiac insult and optimizing cancer treatment. Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are commonly used for patients on pazopanib. Although it has been proposed that ACEIs and ARBs work synergistically with antiangiogenic therapies to inhibit tumor growth, a survival benefit was not demonstrated in a retrospective study of 35 advanced patients with metastatic RCC who received pazopanib with or without one of these antihypertensive medications. 35, 39 Dihydropyridine calcium channel blockers are also commonly used to manage pazopanib-induced HTN; however, nifedipine should be used with caution as it is an inducer of VEGF secretion. 40, 41 Nondihydropyridine blockers such as verapamil and diltiazem are contraindicated with angiogenesis inhibitors due to inhibition of CYP3A4. 40, 41 A combination of b-blockers and hydralazine may also be used to manage pazopanib-induced HTN, especially for patients with left ventricular dysfunction or arrhythmia. 25, 42 More prospective clinical studies are needed in order to develop evidence-based treatment guidelines for managing pazopanib-induced HTN.
Potential mechanisms of pazopanib-induced HTN
Imbalance of vasoconstrictors and vasodilators. Basal VEGF receptor 2 signaling is believed to inhibit the production of endothelin 1, a potent vasoconstrictor, although the exact mechanism is unknown ( Figure 1) . 43 Inhibition of VEGF receptor 2 by pazopanib may lead to increased endothelin 1 levels in circulation, causing sustained vasoconstriction. In rats and humans, levels of circulating endothelin 1 were elevated due to treatment with sunitinib. 44 In humans, blocking the endothelin 1 receptor resulted in reduced peripheral resistance and improved cardiac output. [45] [46] [47] In rats, pretreatment with an endothelin receptor type A antagonist prevented linifanibinduced rise in blood pressure. 44, 48 These studies demonstrate the impact of endothelin 1 on the cardiovascular system, which can be antagonized by inhibition of VEGF receptor-2. Pazopanib should be scrutinized for its effects on nitric oxide and endothelin-1, as this drug is a potent inhibitor of VEGF receptor 2 (similar to sunitinib).
Capillary rarefaction. A second proposed mechanism of pazopanib-induced HTN is capillary rarefaction (reduction in capillary density) leading to increased peripheral resistance and afterload. Vascular endothelial growth factor is normally secreted from cardiomyocytes and acts on endothelial cells in a paracrine manner by way of VEGF receptors (Figure 1) . 49, 50 It has been demonstrated that paracrine and autocrine VEGF signaling is critical to the maintenance of newly differentiated microvasculature and the proliferation of endothelial cells [51] [52] [53] [54] as well as cardiomyocyte survival. 55, 56 Pazopanib inhibition of VEGF signaling may lead to endothelial dysfunction and regression of capillary networks. Accordingly, reduced capillary density and impaired angiogenesis are directly involved in the development of HTN. 57 Therefore, it is possible that the hypertensive effects of pazopanib are due to endothelial cell dysfunction leading to capillary rarefaction.
Direct renal impairment.
A third proposed mechanism of pazopanib-induced HTN is renal impairment leading to activation of the renin-angiotensin-aldosterone system. In addition to the coronary microvasculature, it has been demonstrated that VEGF signaling is vital to the proliferation of renal glomeruli endothelial cells. [58] [59] [60] [61] Therefore, it is expected that pazopanib could lead to capillary rarefaction in renal glomeruli with an increased secretion of renin from the juxtaglomerular apparatus, leading to downstream production of angiotensin II and systemic vasoconstriction. However, no experimental evidence supports this humoral-based hypothesis to date. 62 In fact, plasma renin levels significantly decreased in rats treated with sunitinib, and the coronary microvasculature in these rodents became less responsive to exogenous angiotensin II. 44 Sunitinib-induced blood pressure elevation in humans was not accompanied by renal impairment, suggesting that the reninangiotensin-aldosterone system was likely not involved with this mechanism of HTN. 44 In support of this conclusion, treatment of humans with sorafenib did not lead to a change in serum levels of aldosterone, plasma renin, endothelin 1, or urotensin II. 63 This study concluded that the hypertensive effects of sorafenib are independent of the renin-angiotensinaldosterone system. 63 However, it is worth investigating the involvement of this mechanism in pazopanib, as each TKI should be assessed on a case-by-case basis considering that the kinase selectivity profile of each TKI is variable 64 and that pazopanib-induced HTN is generally manageable by treatment with antihypertensives. 9, 15, 22, 35 
QT Interval Prolongation
Anticancer drug development is a burdensome task that requires many years and billions of dollars, and eventually very few are approved by the FDA. 65 QT interval prolongation, a cardiac toxicity that increases the risk for the development of malignant ventricular tachyarrhythmias (especially Torsades de Pointes, ventricular fibrillation, and sudden cardiac death), 66 is the most common reason for FDA delayed/nonapproval or withdrawal of several anticancer drugs. 67 Numerous VEGF receptor TKIs have been associated with the development of QT interval prolongation. [68] [69] [70] Hence, scrupulous monitoring of QT interval prolongation is mandatory not only to assess the risk of serious cardiac toxicities of anticancerous agents but also to ascertain whether allocating further resources to the development of these agents is worthwhile. 65 Animal studies have demonstrated that adult male rats given pazopanib showed a QTc interval prolongation of around 30 milliseconds when compared to control animals 3 hours after drug administration (99.93 + 3.62 milliseconds versus 131.23 + 12.21 milliseconds, respectively; P < .001). 71 Notably, metoprolol or diltiazem cotreatment significantly prevented the QT prolonging effect of pazopanib.
71 Figure 1 . Vascular endothelial growth factor (VEGF) signaling in endothelial cells is vital for cell survival and vasodilation. Vascular endothelial growth factor binds to VEGF receptor 2 (VEGFR-2) inducing a conformational change that activates Src, phosphoinositide 3-kinase (PI3K), and phospholipase C (PLC; green arrows). Phosphoinositide 3-kinase activity is a significant suppressor of apoptosis, leading to cell survival (green arrow). Additionally, PI3K is an activator of protein kinase B (AKT) which stimulates the production nitric oxide (NO) through activation of endothelial NO synthase (eNOS), leading to vasodilation (green arrows). Phospholipase C contributes to vasodilation through activation of cyclooxygenase 2 (COX2) which produces prostacyclin 2 (PGI 2 ; green arrows). Pazopanib inhibits the intracellular ATP-binding domain of VEGFR-2 (red arrow). Activation of VEGFR-2 suppresses the production of endothelin-1 (a potent vasoconstrictor; red arrow) by an unknown mechanism.
The incidence of QT interval prolongation is rare in pazopanib-treated patients compared to other TKI-treated patients. Notably, in sunitinib-treated patients compared to controls, the incidence of QT interval prolongation was 2% versus 0.2% respectively, with a relative risk of 9.01 (95% confidence interval [CI] 1.15-70.7; P value ¼ .04). Furthermore, the incidence of QT interval prolongation for vandetanib was much higher than controls (8% and 1.2%, respectively). 10 In a phase 3 trial of 435 patients treated with pazopanib, 1% of the patients developed QT interval prolongation (defined as QT interval !500 milliseconds) and Torsades de Pointes. However, a trial-level meta-analysis of randomized phase 2 and 3 trials comparing several VEGF receptor TKIs demonstrated that there was no statistically significant increase in the relative risk of QT interval prolongation in pazopanib-treated patients versus controls. The lack of significance of these data might be attributed to the power of the study, as only 2 trials (totaling 804 patients) were pooled in the meta-analysis. 6, 8, 10 Although the incidence of pazopanib-induced QT interval prolongation is relatively low, patients with cancer are at an increased risk of prolonged QT interval owing to older age, underlying disease, and concomitant medications. 72 Furthermore, these patients may experience treatment-associated hepatic dysfunction that impedes drug clearance and metabolism. 8, 65, 73 Additionally, diarrhea is one of the most common side effects reported with pazopanib-treated patients 8, 22, 24 which could result in QT interval prolongation through electrolyte derangements. 74 The prescription information for pazopanib recommends precise risk assessment in patients with a history of QT interval prolongation and/or receiving antiarrhythmics with pretreatment of electrolytes if necessary and periodic electrocardiogram (ECG) monitoring.
14 Pazopanib is currently listed as a drug that can cause QT prolongation, but there is a lack of evidence for the risk of Torsades de Pointes development. 75 Electrocardiography monitoring. Due to the incidence of QTc interval prolongation associated with pazopanib and the increased risk of Torsades de Pointes, electrolyte levels should be optimized (K þ > 4 milliequivalents and Mg 2þ > 2 milliequivalents) prior to treatment with periodic assessment of laboratory test results and monthly ECG monitoring. There is a paucity of evidence regarding the correlation between duration of pazopanib exposure and QTc prolongation 10 ; however, one double-blind, placebo-controlled study of 96 patients randomized to pazopanib versus moxifloxacin found a concentration-independent prolongation of the QTc interval that occurred within 9 days of starting pazopanib. 33 Although this study used supratherapeutic concentrations of pazopanib, we would recommend electrolyte level monitoring and ECG monitoring at baseline and after 1 month of pazopanib treatment. Evidence of QTc prolongation or other ECG abnormalities may warrant a dose reduction in pazopanib with more frequent surveillance.
Potential mechanisms of pazopanib-induced QT interval prolongation. Pazopanib was recently found to inhibit downstream enzymes B-RAF 76 and C-RAF 77 in an off-target manner (Figure 2 ), which may be responsible for its effect on systolic function. The RAF kinases are cardioprotective and promote cardiomyocyte growth and survival. 78, 79 Inhibition of these kinases likely contributes to cardiovascular toxicity, as cardiac-specific C-RAF knockout mice have increased cardiomyocyte apoptosis accompanied by left ventricular systolic dysfunction and dilation of the heart. 80 B-RAF activity is a strong mediator of human ether-a-go-go-related gene (hERG) channel expression, 81 and selective inhibition of B-RAF by vemurafenib has been associated with prolonged QT interval in humans. 82 Mechanistically, it has been proposed that B-RAF inhibition may lead to a compensatory increase in cyclic adenosine monophosphate (AMP) leading to overactivation of protein kinase A, an enzyme that phosphorylates hERG channels and reduces their ability to open during action potential voltages-prolonging repolarization period and contributing to prolonged QT interval. 79 This mechanism was proposed based on the potent inhibition of B-RAF by sorafenib. Pazopanib also inhibits this enzyme 76 in an off-target manner and should be closely scrutinized for modifying hERG channel activity due to the incidence of prolonged QT interval in pazopanib-treated patients.
Heart Failure
Heart failure and cancer represent 2 major causes of morbidity and mortality in the Western population, imposing a burden on the world economy. [82] [83] [84] [85] [86] The global economic cost of HF in 2012 was approximately US$108 billion per annum. 83 Heart failure is the leading cause of hospitalization each year in the United States and Europe, [87] [88] [89] affecting nearly 5.7 million people in the United States with an incidence of 670 000. 82, 87, 90 Cancer and cardiovascular diseases share many common risk factors, and patients with cancer are more susceptible to develop HF in general. 86, 91 Of note, previous studies have linked VEGF receptor TKIs with HF development. 23, 92 A phase 3 randomized clinical trial that compared pazopanib and sunitinib as first-line treatment for metastatic RCC showed that HF occurred in 11% (42 out of 548) and 13% (47 out of 544) of patients receiving pazopanib and sunitinib, respectively. Notably, about half of the patients developed HF with reduced ejection/systolic dysfunction. 7 Myocardial dysfunction was defined as !15% absolute decline in left ventricular ejection fraction (LVEF) compared to normal or !10% decline in LVEF compared to baseline or the development of cardiac dysfunction symptoms. 7 The phase 3 randomized clinical trial Pazopanib Versus Placebo in patients with STS whose disease has progressed during or following prior therapy (PALETTE, ClinicalTrials.gov, number NCT00753688) found that 5% of patients on placebo developed HF compared to 11% of patients on pazopanib. Myocardial dysfunction was defined using the aforementioned criteria except for !5% instead of !10% decline in LVEF compared to baseline. 6 In another contemporary study, 6% and 20% of patients developed HF and reduced LVEF after receiving pazopanib, respectively. 35 A recent comprehensive meta-analysis of 36 trials provided some insight into the overall incidence and risk of HF development in different patients with cancer treated with VEGF receptor TKIs. The study concluded that there was a significantly increased risk for the development of HF in patients with cancer treated with VEGF receptor TKIs, and thus these patients should be closely monitored for the development of HF signs and symptoms. 12 The incidence of all grade HF (defined according the CTCAE v2.0 or v3.0) and high-grade (!grade 3) HF in patients receiving pazopanib was 6.1 and 1.5, respectively. The odds ratio of all grade HF development for the pazopanib subgroup was 2.4 (95% CI,1.01-5.69; P value ¼ .047) while that of high-grade HF was 4.52 (95% CI, 0.06-299.3: P value ¼ .51). 12 Interestingly, a recent report of a 47-year-old male patient with metastatic RCC with no significant past medical history showed an improvement in his LVEF from 20% to 25% to 43% within 7 months after starting a low dose of pazopanib (400 mg/ d) uptitrated to 800 mg/d. 93 To date, this is the only known case of RCC wherein the patient experienced a significant improvement in cardiac function after pazopanib use and showing good tolerability to pazopanib with an ejection fraction as low as 20% to 25%, a factor that has limited pazopanib use in similar scenarios. 93 This raises the question of whether pazopanib use should be precluded in low ejection fraction states or could be used in gradually uptitrated doses. 93 In line with this, a recent study compared the quality of life and progression-free survival Figure 2 . Pazopanib inhibits the intracellular ATP-binding domain of many growth factors (red arrow) due to the high conservation of this domain across the kinome. Basal activity of these receptors contributes to cell survival and proliferation through the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR1 pathways (green arrows). Protein kinase B (AKT) is a suppressor of Bcl-2 associated death promoter (BAD; red arrow), an inducer of apoptosis. Mechanistic target of rapamycin 1 (mTOR1) activity contributes to cell growth and hypertrophy (green arrow). Pazopanib also inhibits nonreceptor kinases RAF-1 and B-RAF (red arrows).
in patients with STS on low-dose pazopanib with the PAL-ETTE phase 3 study. 94 The study concluded that pazopanib can be initially started at low doses with gradual increments and careful monitoring of side effects. 94 These data, while intriguing, will need to be confirmed in larger prospective multicenter studies.
The true incidence of HF is unclear, as more prospective studies are needed with accurate cardiovascular monitoring to precisely quantify the incidences of asymptomatic and symptomatic cardiac dysfunction. Moreover, isolated and coexisting right ventricular dysfunction is often unreported because such patients are usually excluded from clinical trials. 95 The American College of Cardiology/American Heart Association guidelines state that patients with cancer having HF should be managed with standard HF therapies regardless of their cancer status. 96 Patients should be closely monitored for the development of clinical signs and/or symptoms of HF in addition to pretreatment and periodic on-treatment assessments of LVEF, particularly high-risk patients and those with a history of anthracycline use.
11,95
Echocardiography monitoring. Periodic echocardiography monitoring of patients on pazopanib may prove to be a useful method for detecting early signs of cardiotoxicity. A recent retrospective study that followed 23 97, 98 may indicate early signs of TKI-induced cardiotoxicity. However, these results must be confirmed in a longer term study and correlated with reduction in LVEF. 11 Interestingly, the study found that the right ventricle is more vulnerable to chemotherapy (in the absence of pulmonary HTN) than the left side which may be due to its thinner wall.
11 Notably right-sided HF is often underreported because these patients are excluded from clinical trials. 95 Therefore, we recommend close echocardiogram surveillance of all patients receiving pazopanib at baseline, 1 month, and 3 months, and any abnormalities may warrant a dose reduction.
Potential mechanisms of pazopanib-induced systolic dysfunction. Fibroblast growth factor signaling in the heart is essential for normal physiologic processes. 99, 100 Notably, pazopanib inhibition of fibroblast growth factor receptor 1 may be responsible for its adverse effects on systolic function, as this receptor may have a role in contractility. Acute expression of this receptor increases cardiomyocyte contractility and chronic expression leads to significant cardiomyocyte hypertrophy and preservation of systolic function. 101 By this mechanism, pazopanibinduced systolic dysfunction may be a result of off-target inhibition of fibroblast growth factor receptor 1. Therefore, it will be worthwhile to determine whether pazopanib perturbs cardiomyocyte contractility and whether this effect is due to inhibition of fibroblast growth factor receptor 1.
Furthermore, VEGF blockade causes endothelial dysfunction and transition from physiological to pathological hypertrophy, a process that if prolonged leads to dilated cardiomyopathy and end-stage HF. [102] [103] [104] Additionally, PDGF receptor-b signaling in the myocardium plays a critical role in stress-induced coronary angiogenesis. 105 Sunitinib-induced dysfunction of the coronary microvasculature was attributed to the inhibition of PDGF receptor-b signaling in pericytes. 106 Therefore, it is possible that pazopanib treatment leads to pathological hypertrophy due to its ability to inhibit these key proangiogenic pathways.
Myocardial Ischemia, Apoptosis, and Thrombosis
Myocardial infarction is a leading cause of death in the United States with an incidence of approximately 580 000 new cases and 210 000 recurrent attacks each year. 107 From 2000 to 2010, the number of hospital discharges for coronary heart disease was about 1 340 000 with direct and indirect costs estimated at US$10.4 billion which are expected to double by 2030. 108 Recent studies have associated pazopanib with the onset of MI. In a phase 3, placebo-controlled trial in patients with metastatic RCC and STS, the incidence of treatment-related MI/ ischemia was about 2% 8 and 1%, respectively (ClinicalTrials.-gov Identifier: NCT00753688). In addition, cerebrovascular accidents and transient ischemic attacks occurred in <1% of pazopanib-treated patients with metastatic RCC. 8 Likewise, thrombosis developed in <1% of patients receiving pazopanib for advanced and recurrent cervical cancer. 108 Furthermore, venous thromboembolic events were reported in 5% of the patients with STS on pazopanib.
6 Therefore, despite the low incidence of thromboembolic events and acute MI development reported with pazopanib, it should be used with caution in patients with history of coronary artery disease, previous embolic stroke, or at high risk of thromboembolic events. 14 Potential mechanisms of pazopanib-induced myocardial ischemia, apoptosis, and thrombosis. Vascular endothelial growth factor signaling is vital for endothelial cell proliferation and coronary angiogenesis secondary to stretch-induced cardiac hypertrophy 56, 102, 104, 109 as well as cardiac remodeling after ischemic injury. 55 Even in nonpathologic states, autocrine VEGF signaling is essential to endothelial cell survival (Figure 1) . 53 Pazopanib may be responsible for apoptosis of endothelial cells, which are prone to coagulation [110] [111] [112] and may be responsible for thromboembolic and ischemic events in pazopanib-treated patients. Pazopanib inhibition of VEGF signaling may also increase blood viscosity through overproduction of erythropoietin, exacerbating risk for thrombosis. 113, 114 Normal fibroblast growth factor signaling in the heart is vital for cell proliferation, differentiation, survival, and angiogenesis. 99, 100 Fibroblast growth factor 2 knockout mice develop thrombocytosis, poor vascular function, and an impaired cardiac ability to hypertrophy in response to ischemic 115 and pressure overload conditions. 116 These studies demonstrate the importance of fibroblast growth factor signaling in the heart, which may be adversely affected by pazopanib. This inhibition may significantly contribute to the hypertensive and anti-angiogenic properties of pazopanib, as well as apoptosis, endothelial cell dysfunction, and pathological remodeling.
In addition to its effects on endothelial cells, pazopanib inhibition of the receptor tyrosine kinase/phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway may lead to activation of cardiomyocyte apoptotic pathways, as AKT is responsible for inactivating BAD, a proapoptotic protein. 117, 118 In the heart, AKT activation reduced cardiomyocyte apoptosis and drastically preserved cardiac function in an ischemic rat model. 119 In mice, activation of the PI3K/AKT/mechanistic target of rapamycin pathway prevented adriamycin-induced cardiomyocyte apoptosis and autophagy. 120 In a rabbit model of pressure overload, exogenous VEGF prevented cardiomyocyte apoptosis and preserved cardiac function, 121 possibly through improved VEGF receptor-2/PI3K/AKT regulation of Bcl-2 proteins. These studies implicate the cardiomyocyteprotective role of PI3K/AKT signaling during cardiac stress. However, while pazopanib is a potent inhibitor of VEGF receptor-2 and other receptor tyrosine kinases, it may not necessarily lead to cardiomyocyte apoptosis in patients, as the PI3K/AKT pathway is activated by many factors in the heart, 122 several of which are spared by pazopanib. Furthermore, VEGF may contain receptor-independent cardioprotective effects. In an ischemic rat model, VEGF activated PI3K through a receptor-independent mechanism; however, Bcl-2 was not activated in this setting. 123 Further research is warranted to determine whether pazopanib induces cardiomyocyte apoptotic pathways through inhibition of receptor tyrosine kinase/PI3K/AKT signaling.
Conclusion
Pazopanib is an effective treatment for metastatic RCC. 35 The use of pazopanib will continue to increase due to the aging US population and the potential FDA approval of pazopanib for the treatment of other malignancies. As the significant cardiovascular side effect profile of pazopanib is now coming to light, it is imperative to elucidate the mechanisms underlying pazopanib-induced toxicity in order to advance the field of cardio-oncology. Gaining a broader perspective of these mechanisms will allow for the development of appropriate surveillance strategies and possible diagnostic biomarkers to allow us to monitor and treat patients at a more granular level. If a patient has a cardiovascular adverse event such as MI, HF, or Torsades de Pointes while on pazopanib, we recommend immediate cessation of pazopanib and treatment according to the standard of care. Ultimately, the goal is to keep patients on these lifesaving therapies while simultaneously giving us the insight to know when to modulate or discontinue therapy prior to significant cardiac insult.
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